Corramedical Opens Applications for 2025 Biopsy Catchment Biobank Investigators Award

June 23, 2025 11:30 AM EDT | By EIN Presswire
 Corramedical Opens Applications for 2025 Biopsy Catchment Biobank Investigators Award
Image source: EIN Presswire
LA JOLLA, CA, UNITED STATES, June 23, 2025 /EINPresswire.com/ -- Corramedical, Inc., a leader in innovative biopsy specimen technologies, is now accepting applications for the 2025 Biopsy Catchment Biobank Investigators Award. This competitive grant program will award a total of $15,000 to support original research exploring the biobanking and biomarker potential of dislodged tumor cells recovered using the Crow’s Nest™ Biopsy Catchment System.

The Crow’s Nest system is a portable, disposable tool designed to recover a second specimen — composed of viable, analyzable tumor cells — from material that is typically discarded during core needle biopsies. This minimally handled specimen, unexposed to formalin, represents a high-quality resource for biobanks and downstream ‘omics research.

Corramedical invites researchers to submit 500-word proposals demonstrating how this recovered cellular material can be incorporated into forward-thinking, integrated biobanking workflows. Proposals should highlight applications across genomics, transcriptomics, proteomics, or other emerging multiomic fields and articulate how these workflows could add value to both (a) biobank infrastructure and (b) biomarker discovery pipelines in academia and pharma.

Key Award Details:
• Award Amount: Three (3) recipients will receive $5,000 each.
• Additional Support: Each award includes Crow’s Nest devices, free of charge, in quantities specific to the winning protocol.
• Eligibility: Open to U.S.-based applicants. Concurrent funding from other sources does not disqualify applicants.
• Consultation: Applicants may request a complimentary project consultation with a Corramedical-affiliated pathologist or technical staff member.
• Acknowledgment: Recipients are expected to cite the Crow’s Nest Biopsy Catchment System in the methods section of resulting publications.

Application Process:
• Deadline: Applications will be reviewed on a rolling basis beginning July 1, 2025, and accepted throughout the remainder of the year.
• Submission: Proposals (max 500 words) should be submitted via email to [email protected].
• Contact: For inquiries, contact +1-833-4-BIOPSY or visit www.corramedical.com/grant-opportunities.

“Each core needle biopsy represents an opportunity not only for diagnosis but for discovery,” said Dr. Wilfrido Mojica, Corramedical Chief Technology Officer. “This award encourages creative minds in biobanking to help redefine what’s possible with the cells we already extract — and usually discard.”

For updates, find Corramedical online at www.corramedical.com, and follow us on LinkedIn at https://www.linkedin.com/company/corramed/ Corramedical is an EvoNexus portfolio company.

Crow’s Nest™, One Biopsy, Many Answers™, and Biopsy Catchment™ are trademarks of Corramedical, Inc.

Nathan Edwards
Corramedical, Inc.
+1 833-424-6779 ext. 1
email us here
Visit us on social media:
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media Incorporated (“Kalkine Media, we or us”), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used in the Content are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.